SCHEMBL24257786

SCHEMBL24257786

CCOC(=O)CNC(=O)c1ncc(-c2cnn(C3CCN(C(=O)OC(C)(C)C)CC3)c2)c(C)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 4/20 0.44
TNK2 Q07912 1/20 0.42
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EGFR P00533 1/20 0.40
LCK P06239 1/20 0.40
JAK3 P52333 1/20 0.40
BTK Q06187 1/20 0.40
TTK P33981 2/20 0.40
FGFR1 P11362 2/20 0.40
FGFR2 P21802 2/20 0.40
FGFR4 P22455 2/20 0.40
FGFR3 P22607 2/20 0.40
KDR P35968 2/20 0.40
FLT3 P36888 2/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30546843 1.00 MET (0.44) METTNK2CCNCCDK8DDB1
SCHEMBL24257505 0.92 TNK2 (0.45) METTNK2CCNCCDK8DDB1
SCHEMBL24257712 0.86 MEN1 (0.48) METTNK2L3MBTL1TTKLMNA
SCHEMBL30452371 0.86 MEN1 (0.48) METTNK2L3MBTL1TTKLMNA
SCHEMBL24257746 0.85 ABL1 (0.40) METJAK3BTKFGFR1LMNA
SCHEMBL24257797 0.75 HSP90AA1 (0.41) JAK3FLT3LMNA
SCHEMBL24257611 0.74 IRAK4 (0.41) JAK3FGFR1
SCHEMBL24257696 0.74 TNK2 (0.48) METTNK2CCNCCDK8DDB1
SCHEMBL24257770 0.73 ALDH1A1 (0.39) TTKKDRLMNA
SCHEMBL24257732 0.73 CCNC (0.49) METTNK2CCNCCDK8DDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116670131-A PHD inhibitor compounds, compositions, and methods of use 阿克比治疗有限公司 2023-08-29 CN disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed